Madopar (Benserazide Hydrochloride, Levodopa)

Levodopa is a precursor of dopamine that crosses the blood‑brain barrier. Once inside the central nervous system it is converted to dopamine, replenishing the neurotransmitter that is deficient in Parkinsonian disorders. Benserazide prevents this conversion in the periphery, allowing more levodopa to reach the brain.

The appropriate dose of Madopar is individualized by the prescribing clinician based on disease severity, patient response, and tolerability. Dosage adjustments are made gradually to achieve optimal symptom control while minimizing side effects.

Safety data for Madopar in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Madopar product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Madopar combines levodopa with benserazide, offering more efficient central dopamine delivery than levodopa alone. Compared with dopamine agonists, it generally provides stronger symptom relief but may have a higher incidence of motor complications such as dyskinesia. Choice of therapy depends on individual patient factors and treatment goals.

Madopar tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original container, protect from moisture and direct light, and ensure the packaging remains tightly closed until use.

Madopar is taken orally, usually with a full glass of water. It can be taken with or without food, but a consistent routine helps maintain stable plasma levels. Patients should follow the dosing schedule prescribed by their healthcare provider.

Serious risks include the development of dyskinesia, hallucinations, severe hypotension, neuroleptic malignant‑like syndrome, and significant mood changes such as depression or suicidal thoughts. Prompt medical evaluation is required if any of these symptoms arise.

Madopar is contraindicated in patients with known hypersensitivity to levodopa, benserazide, or any excipients. It should also be avoided in individuals taking non‑selective MAO inhibitors, and caution is advised for those with severe cardiovascular disease, uncontrolled psychiatric disorders, or significant renal/hepatic impairment.